Yayın:
Candidate biomarkers associated with circulating tumor cell status in metastatic colorectal cancer

dc.contributor.authorDogan, Berkcan
dc.contributor.authorPirim, Dilek
dc.contributor.authorIsik, Oezgen
dc.contributor.authorEvrensel, Tuerkkan
dc.contributor.orcid0000-0001-8061-8131
dc.contributor.orcid0000-0002-0522-9432
dc.contributor.researcheridT-7494-2017
dc.contributor.researcheridAAD-5249-2020
dc.contributor.researcheridABA-4957-2020
dc.date.accessioned2025-10-14T06:22:31Z
dc.date.issued2025-04-01
dc.description.abstractBackgroundColorectal cancer (CRC) ranks as the third most prevalent cancer worldwide. Recent studies suggest the promising potential of microRNAs (miRNA) in predicting the status of circulating tumor cells (CTC), and their combined analyses could pave the way for significant advancements in assessing the risk of metastatic cancer. Here, we investigate the circulating miRNA signatures associated with CTC status in metastatic CRC (mCRC).MethodsThe CTC status of mCRC patients was assessed using AdnaTest ColonCancer technology, which detects tumor cells using an immunomagnetic approach and characterizes them based on colon-specific surface markers. The miRNA profiles were analyzed using the Agilent miRNA microarray in 8 CTC-positive, 8 CTC-negative, and eight healthy individuals. The functional implications of dysregulated miRNAs and their interactions with target mRNAs, TFs, and lncRNAs were determined through a comprehensive in silico analysis. Candidate miRNAs that were differentially expressed in CTC-positive and CTC-negative groups, which have prior evidence for their role in CRC biology, were validated using qPCR.ResultsWe identified two groups of dysregulated miRNAs associated with CTC status and multiple candidate biomarkers in suggested miRNA regulatory networks. Three miRNAs (hsa-miR-199a-5p, hsa-miR-326, hsa-miR-500b-5p), which were downregulated in the CTC-positive group compared to the CTC-negative group, were confirmed by qPCR and prioritized as candidate predictors of CTC status in mCRC.ConclusionOur findings suggest biomarker candidates that can be used to predict CTC status in individuals with mCRC. This might also provide new insights into new translational medicine applications in the management of mCRC through miRNA-based CRC-associated CTC detection.
dc.identifier.doi10.1002/jcla.70013
dc.identifier.issn0887-8013
dc.identifier.issue7
dc.identifier.scopus2-s2.0-105000385699
dc.identifier.urihttps://doi.org/10.1002/jcla.70013
dc.identifier.urihttps://hdl.handle.net/11452/55499
dc.identifier.volume39
dc.identifier.wos001464450700005
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley
dc.relation.journalJournal of clinical laboratory analysis
dc.subjectMIR-326
dc.subjectSUPPRESSOR
dc.subjectEXPRESSION
dc.subjectCARCINOMA
dc.subjectDIAGNOSIS
dc.subjectGROWTH
dc.subjectbiomarker
dc.subjectcirculating tumor cells
dc.subjectmetastatic colorectal cancer
dc.subjectmicroarray
dc.subjectmicroRNA
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectMedical Laboratory Technology
dc.subjectMedical Laboratory Technology
dc.titleCandidate biomarkers associated with circulating tumor cell status in metastatic colorectal cancer
dc.typeArticle
dspace.entity.typePublication
local.indexed.atWOS
local.indexed.atScopus

Dosyalar